About
Personalized medicine through molecular diagnostics and innovation
Areas of Focus
Categories
DiagnosticsNJ, NY, PA
Team (8)
Christopher McCarthy
Chief Financial Officer and Chief Operating Officer
Interpace Biosciences
executive
Joseph Keegan, Ph.D.
Director
Interpace Biosciences
team_member
Nicole Massoll, MD
Chief Medical Officer
Interpace Biosciences
executive
Ron Rocca
Director
Interpace Biosciences
team_member
Stephen J. Sullivan
Director
Interpace Biosciences
team_member
Syd Finkelstein, MD
Chief Scientific Officer
Interpace Biosciences
executive
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
186
By Phase
PHASE3: 1PHASE1: 3PHASE1/PHASE2: 1PHASE2: 1
By Status
COMPLETED: 3ACTIVE_NOT_RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06263478Lead Sponsor
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
PHASE3Active, not recruiting
21 participants
Started: Jul 30, 2024 · Completed: Mar 30, 2027
NCT05068466Lead Sponsor
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
PHASE1Completed
30 participants
Started: Oct 21, 2021 · Completed: Jan 25, 2022
NCT04674748Lead Sponsor
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
PHASE1Terminated
3 participants
Started: Feb 3, 2021 · Completed: May 13, 2022
NCT04661007Lead Sponsor
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
PHASE1/PHASE2Active, not recruiting
72 participants
Started: Dec 15, 2020 · Completed: Dec 31, 2026
NCT04434937Lead Sponsor
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
PHASE2Completed
42 participants
Started: Sep 30, 2020 · Completed: Oct 13, 2023
Locations (1)
Headquarters
Parsippany, NJ, United States
Map
Loading map...